Cargando…

Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report

RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Karino, Kohei, Fujieda, Yuichiro, Kawamura, Takuya, Abe, Nobuya, Shimoyama, Shuhei, Kono, Michihito, Kato, Masaru, Yasuda, Shinsuke, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310527/
https://www.ncbi.nlm.nih.gov/pubmed/30544475
http://dx.doi.org/10.1097/MD.0000000000013563
Descripción
Sumario:RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma. INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the “autoimmune tumor marker” in patients with inflammatory myopathy.